Dhami J, Hirshfield KM, Ganesan S, Hellmann M, Rojas V, Amorosa JK, Riedlinger GM, Zhong H, Ali SM, Pavlick D, Elvin JA, Rodriguez - Rodriguez L. Comprehensive genomic profiling aids in treatment of
a metastatic endometrial cancer.
Currently, the CDK9 inhibitor flavopiridol is being evaluated in several phase I and II clinical trials for its anti-
cancer effects either as a single agent or in combination with other drugs in treatment of esophageal
cancer, B - cell chronic lymphocytic leukemia,
endometrial carcinoma, recurrent /
metastatic squamous cell carcinoma and most relevantly, previously treated locally advanced or
metastatic breast
cancer (http://www.cancernetwork.com/review-article/current-clinical-trials-flavopiridol/page/0/2).